Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


CardioDx Launches Gene Test For Obstructive Coronary Disease

This article was originally published in The Gray Sheet

Executive Summary

CardioDx is gradually rolling out its Corus CAD gene expression test, which quantifies the likelihood of obstructive coronary artery disease in patients with stable chest pain and no previous history of cardiac disease

You may also be interested in...

Financings In Brief

CardioDx raises $58 million for heart test marketing. OmniGuide gets $35 million for surgical laser products. More financings.

News In Brief

CardioNet buys CardioCore Lab. HeartWare gears for HVAD rollout. Zimmer prevails in Genzyme patent case. CardioDx gains Corus CAD heart test Medicare coverage. More news briefs.

Financings In Brief

Cameron Health raises $107 million

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts